Dimerix Ltd
ASX:DXB
Prices of ASX stocks are not being updated. The latest DXB price on Alpha Spread is from Oct 14, 2026. Financials, forecasts and intrinsic value keep updating.
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Dimerix Ltd
ASX:DXB
|
AU |
|
N
|
Northrop Grumman Corp
XMUN:NTH
|
US |
Intrinsic Value
The intrinsic value of Dimerix Ltd (DXB) under the Base Case is 1.77 AUD per share.
Compared with the last price of 0.21 AUD on Oct 14, the stock appears
Undervalued by 88% .
The intrinsic value is calculated using valuation multiples.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Dimerix Does
Dimerix Ltd is a drug-development company focused on kidney disease and other serious conditions. It does not sell a finished medicine to patients; instead, it develops drug candidates and the scientific tools used to find new treatments. Its lead work centers on DMX-200, a kidney-disease therapy in clinical development, and on its receptor-based discovery platform, which it uses to identify and test new drug targets.
- Headquarters
- Australia AU
- IPO date
- Jul 5, 1989
Earnings Waterfall
Dimerix Ltd
The intrinsic value for Dimerix Ltd (DXB) under the Base Case is 1.77 AUD.
Compared with the last price of 0.21 AUD on Oct 14, the stock appears Undervalued by 88% .